Discontinued — last reported Q4 '25
Investing
Purchases of equity securities
Over 2 years (FY 2021 to FY 2025), Purchases of equity securities shows a downward trend with a -100.0% CAGR.
Analysis
StatementCash Flow Statement
SectionInvesting
CategoryCapital Allocation
SignalContext dependent
VolatilityVolatile
First reportedQ1 2021
Last reportedQ4 2025Feb 11, 2026
How to read this metric
Reflects corporate strategy regarding external growth, partnerships, or strategic minority investments.
Detailed definition
Captures cash outflows specifically directed toward the acquisition of equity stakes in other entities. This reflects st...
Peer comparison
Varies based on corporate development strategy and M&A activity.
Metric ID:
purchases_of_equity_securitiesHistorical Data
13 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q1 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0 | $4.6M | $0 | $7.7M | $31.3M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| QoQ Change | — | — | -100.0% | — | +306.5% | -100.0% | — | — | — | — | — | — | — |
| YoY Change | — | — | — | — | +306.5% | -100.0% | — | — | — | — | — | — | — |
Range$0 – $31.3M
Avg YoY Growth+103.2%
Median YoY Growth+103.2%
Purchases of equity securities at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's purchases of equity securities?
- Neurocrine Biosciences (NBIX) reported purchases of equity securities of $0 in Q4 2025.
- What is the long-term trend for Neurocrine Biosciences's purchases of equity securities?
- Over 2 years (2021 to 2025), Neurocrine Biosciences's purchases of equity securities has grown at a -100.0% compound annual growth rate (CAGR), from $4.6M to $0.
- What does purchases of equity securities mean?
- Cash spent to acquire shares or equity interests in other companies.